Ameliorative effect of pyrrolidinedithiocarbamate on acetic acid-induced colitis in rats

European Journal of Pharmacology

Volumn 554, Issue 1, 2007, Pages 69-77

  Hagar, Hanan H ^a   El Medany, Azza ^a   El Eter, Eman ^a   Arafa, Maha ^a  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

Inducible nitric oxide synthase; Inflammatory cytokine; Nitrite nitrate; Oxidative stress; Pyrrolidinedithiocarbamate; Ulcerative colitis

Indexed keywords

ACETIC ACID; ANTIOXIDANT; GLUTATHIONE; I KAPPA B; INDUCIBLE NITRIC OXIDE SYNTHASE; LACTATE DEHYDROGENASE; LIPID PEROXIDE; MYELOPEROXIDASE; NITRATE; NITRITE; PYRROLIDINE DITHIOCARBAMATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHEMICAL ANALYSIS; COLON; COLON INJURY; CONTROLLED STUDY; DRUG EFFECT; EDEMA; ENTERITIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ULCERATIVE COLITIS; UPREGULATION;

ACETIC ACID; ANIMALS; COLITIS, ULCERATIVE; COLON; GLUTATHIONE; L-LACTATE DEHYDROGENASE; LIPID PEROXIDES; MALE; NITRATES; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; PEROXIDASE; PROLINE; RATS; RATS, WISTAR; THIOCARBAMATES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37849187686     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.09.066     Document Type: Article

References (64)

1. Abreu M.T. The pathogenesis of inflammatory bowel disease: translational implications for clinicians. Curr. Gastroenterol. Rep. 4 (2002) 481-489
2. Baeuerle P.A., and Baltimore D. NF-κB: ten years after. Cell 87 (1996) 13-20
3. Bauerle P.A., and Henkel T. Function and activation of NF-B in the immune system. Ann. Rev. Immunol. 2 (1994) 141-179
4. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., and Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 1620-1624
5. Blau S., Rubistein A., Bass P., Singaram Ch., and Kohen R. Differences in the reducing power along the rat GI tract: lower antioxidant capacity of the colon. Mol. Cell. Biochem. 194 (1999) 185-191
6. Bobin-Dubigeon X., Collin N., Grimaud J.M., Robert G., Le Baut L., and Petit J.Y. Effects of tumor necrosis factor-α synthesis inhibitors on rat trinitrobenzene sulphonic acid-induced chronic colitis. Eur. J. Pharmacol. 42 (2001) 103-110
7. Bossone C., Hosseini J.M., Pineiro-Carrero V., and Shea-Donohue T. Alterations in spontaneous contractions in vitro after repeated inflammation of rat distal colon. Am. J. Physiol.: Gasterointest. Liver Physiol. 280 (2001) G949-G957
8. Boughten-Smith N.K., Evans S.M., Hawkey C.J., Cole A.T., Balsitis M., Whittle B.J., and Moncada S. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet 342 (1993) 338-340
9. Brown S.J., and Abreu M.T. Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease. Curr. Opin. Drug Discov. Dev. 8 2 (2005) 160-168
10. Buege J.A., and Aust S.D. Microsomal lipid peroxidation methods. Enzymologia 52 (1978) 302-310
11. Chatterjee P.K., Di Villa B.R.D., Sivarajah A., McDonald M.C., Cuzzocrea S., and Thiemermann C. Pyrrolidine dithiocarbamate reduces renal dysfunction and injury caused by ischemia/reperfusion of the rat kidney. Eur. J. Pharmacol. 482 (2003) 271-280
12. Cuzzocrea S., Chatterjee P.K., Mazzon E., Dugo L., Serraino I., Britti D., Mazzullo G., Caputi A.P., and Thiemermann C. Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. Br. J. Pharmacol. 135 (2002) 496-510
13. D'Odorico A., Bortolan S., Cardin R., D'Inca R., Martines D., Fettonato A., and Sturniolo G.C. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand. J. Gastroenterol. 36 (2001) 1289-1294
14. Derkz B., Taminiau J., Radema S., Sronkhorst A., Wortel C., Tytgat G., and Van Deventer S. Tumor-necrosis factor antibody treatment in Crohn's disease. Lancet 342 (1993) 173-174
15. Dijkstra G., Moshage H., van Dullemen H.M., de Jager-Krikken A., Tiebosch A.T., Kleibeuker J.H., Jansen P.L., and van Goor H. Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. J. Pathol. 186 (1998) 416-421
16. El Eter E., Hagar H., Al-tuwaijiri A., and Araf M. NF-κb inhibition by pyrrolidine dithiocarbamate attenuates gastric ischemia-reperfusion injury in rats. Can. J. Physiol. Pharm. 83 6 (2005) 483-492
17. Ellman G. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82 (1959) 70-76
18. Elson C.O., Sartor R.B., Tennyson G.S., and Riddell R.H. Experimental models of inflammatory bowel disease. Gastroenterology 109 (1995) 1344-1367
19. Frode-Saleh T.S., and Calixto J.B. Synergistic anti-inflammatory effect of NF-κB inhibitors and steroidal or nonsteroidal antiinflammatory drugs in the pleural inflammation induced by carrageenan in mice. Inflamm. Res. 49 (2000) 330-337
20. Grisham M.B., Jourd' Heuil D., and Wink D.A. Nitric oxide physiological chemistry of nitric oxide and its metabolites. Implication in inflammation. Am. J. Physiol. 276 (1999) G315-G321
21. Grisham M.B., Pavlick K.P., Laroux F.S., Hoffman J., Bharwani S., and Wolf R.E. Nitric oxide and chronic gut inflammation: controversies in inflammatory bowel disease. J. Investig. Med. 50 (2002) 272-283
22. Hersh E.M., Brewton G., and Abrams D. Dithiocarb useful in HIV therapy. Nurs. Times 87 21 (1991) 22-28
23. Hogaboam C.M., Jacobson K., Collins S.M., and Blennerhassett M.G. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am. J. Physiol. 268 (1995) G673-G684
24. Inoue S., Matsumoto T., and Iida M. Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity. Am. J. Gastroenterol. 94 (1999) 2441-2446
25. Jun-Hua L., Jie-Ping Y., Hong-Gang Y., Xi-Ming X., Liang-Liang Y., and Shi-Quan L. Expression and significance of nuclear factor kB p65 in colon tissues of rats with TNBS-induced colitis. World J. Gastroenterol. 11 12 (2005) 1759-1763
26. Kankuri E., Asmawi M.Z., Korpela R., Vapaatalo H., and Moilanen E. Induction of iNOS in a rat model of acute colitis. Inflammation 23 (1999) 141-152
27. Keshavarzian A., Morgan G., Sedghi S., Gordon J.H., and Doria M. Role of reactive oxygen metabolites in experimental colitis. Gut 31 (1990) 786-790
28. Keshavarzian A., Sedghi S., and Kanofsky J. Excessive production of reactive oxygen metabolites by inflamed colon: analysis by chemiluminescence probe. Gastroenterology 103 (1992) 177-185
29. Kitahora T., Suzuki K., Asakura H., Yoshida T., Suematsu M., Watanabe M., Aiso S., and Tsuchiya M. Active oxygen species generated by monocytes and polymorphonuclear cells in patients in Crohn's disease. Dig. Dis. Sci. 33 (1998) 951-955
30. Kruidenier L., and Verspaget H.W. Oxidative stress as a pathogenic factor in inflammatory bowel disease-radicals or ridiculous?. Aliment. Pharmacol. Ther. 16 (2002) 1997-2015
31. Liu S.F., Ye X., and Malik A.B. Pyrrolidine dithiocarbamate prevents I-kappa B degradation and reduces microvascular injury induced by lipopolysaccharide in multiple organs. Mol. Pharmacol. 55 4 (1999) 658-667
32. Loguercio C., D'Argenio G., Delle Cave M., Cosenza V., Della Vale N., Mazzacca G., and Del Vecchio Blanco C. Direct evidence of oxidative damage in acute and chronic phases of experimental colitis in rats. Dig. Dis. Sci. 41 (1996) 1204-1211
33. MacDonald T.T., Monteleone G., and Pender S.L. Recent developments in the immunology of inflammatory bowel disease. Scand. J. Immunol. 51 (2000) 2-9
34. Mccafferty D.M., Mudgett J.S., Swain M.G., and Kubes P. Inducible nitric oxide synthase plays a critical role in resolving intestinal inflammation. Gastroenterology 112 (1997) 1022-1027
35. Millar A.D., Ramton D.S., Chander C.L., Claxson A.W.D., Blades S., Coumbe A., Panetta J., Morris C.J., and Blake D.R. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut 39 (1996) 407-415
36. Miranda K., Espy M.G., and Wink D.A. A rapid and simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 5 (2001) 62-71
37. Mustafa A., El-Medany A., Hagar H., and El-Medany G. Ginkgo biloba attenuates mucosal damage in a rat model of ulcerative colitis. Pharmacol. Res. 53 (2001) 324-330
38. Mullane K.M., Kremer R., and Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J. Pharmacol. Methods 14 (1985) 157-167
39. Nagi M.N., Suneja S.K., and Cook L. Depletion of rat hepatic glutathione and inhibition of microsomal trans-2-Enoyl-CoA reductase activity following administration of Dec-2-ynol and Dec-2-ynoic acid. Arch. Biochem. Biophys. 293 (1992) 71-87
40. Neurath M.F., Fuss I., Schurmann G., Pettersson S., Arnold K., Muller-Lobeck H., Strober W., Herfarth C., and Buschenfelde K.H. Cytokine gene transcription by NF-κB family members in patients with inflammatory bowel disease. Ann. N.Y. Acad. Sci. 859 (1998) 149-159
41. Nurmi A., Lindsberg P.J., Koistinaho M., Zhang W., Juettler E., Karjalainen-Lindsberg M.L., Weih F., Frank N., Schwaninger M., and Koistinaho J. Nuclear factor -kappa B contributes to infarction after permanent focal ischemia. Stroke 35 4 (2004) 987-991
42. Ogata H., and Hibi T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr. Pharm. Des. 9 (2003) 1107-1113
43. Pahl H.L. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18 (1999) 6853-6866
44. Perner A., and Rask-Madsen J. Review article: the potential role of nitric oxide in chronic inflammatory bowel disorders. Aliment. Pharmacol. Ther. 13 (1999) 135-144
45. Podolsky D.K. Inflammatory bowel disease. N. Engl. J. Med. 325 (1991) 1008-1016
46. Rachmilewitz D., Karmeli F., Okon E., and Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut 37 (1995) 247-255
47. Rahman A., Kefer J., Bando M., Niles W.D., and Malik A.B. E-selectin expression in human endothelial cells by TNF-alpha-induced oxidant generation and NF-kappa B activation. Am. J. Physiol. 275 (1998) L 533-L 544
48. Reinecker H.C., Steffen M., Witthoeft T., Pflueger I., Schreibe S., Mac-Dermatt R.P., and Raedler A. Enhanced secretion of tumor necrosis factor-alpha, IL-6 and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and crohn's disease. Clin. Exp. Immunol. 94 (1993) 174-181
49. Rogler G., and Andus T. Cytokines in inflammatory bowel disease. World J. Surg. 224 (1998) 82-89
50. Ross S.D., Kron I.L., Gangemi J.J., Shockey K.S., Stoler M., Kern J.A., Tribble C.G., and Laubach V.E. Attenuation of lung reperfusion injury after transplantation using an inhibitor of nuclear factor -kappa B. Am. J. Physiol., Lung Cell. Mol. Physiol. 297 (2000) L528-L536
51. Sandborn W.J. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev. Gastroenterol. Disord. 5 1 (2005) 10-18
52. Sartor R.B. Pathogenesis and immune mechanisms of chronic inflammatory bowel disease. Am. J. Gastroenterol. 92 (1997) 5S-11S
53. Schreck R., Meier B., Mannel D.N., Droge W., and Baeuerle P.A. Dithiocarbamates as potent inhibitors of nuclear factor-κB activation in intact cells. J. Exp. Med. 175 (1992) 1181-1194
54. Segain J.P., Raingeard de la Bletiere D., Bourreille A., Leray V., Gervois N., Rosales C., Ferrier L., Bonnet C., Blottiere H.M., and Galmiche J.P. Butyrate inhibits inflammatory responses through NF-κB inhibition: implications for Crohn's disease. Gut 47 (2000) 397-403
55. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 120 (2001) 622-635
56. Shusterman T., Sela S., Cohen H., Kristal B., Sbeit W., and Reshef R. Effect of the antioxidant Mesna (2-mercaptoethane sulfonate) on experimental colitis. Dig. Dis. Sci. 48 (2003) 1177-1185
57. Sies H. Glutathione and its role in cellular functions. Free Radic. Biol. Med. 27 (1999) 916-921
58. Southey A., Tanaka S., and Murakami T. Pathophysiological role of nitric oxide in rat experimental colitis. Int. J. Immunopharmacol. 19 (1997) 669-676
59. Strober W., Ludviksson B.R., and Fuss I.J. The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn's disease. Ann. Intern. Med. 128 (1998) 848-856
60. Sunderman F.W. Chelation therapy in nickel poisoning. Ann. Clin. Lab. Sci. 11 (1981) 1-8
61. Sunderman F.W. Therapeutic properties of sodium diethyldithiocarbamate: its role as an inhibitor in the progression of AIDS. Ann. Clin. Lab. Sci. 21 1 (1991) 70-81
62. Ukil1 A., Maity S., Karmakar S., Datta N., Vedasiromoni J.R., and Das P.K. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br. J. Pharmacol. 139 (2003) 209-218
63. Wei-Guo D., Mei O., Jie-Ping Y.U., Jian-Ming X.U., Xiang L., and Yu X.u. Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J. Gastroenterol. 9 6 (2003) 1307-1311
64. Woywodt A., Ludwig D., and Neustock P. Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 11 (1999) 267-276